Skip to search formSkip to main contentSkip to account menu

RB 101

Known as: L-Phenylalanine, N-(2-(((2-amino-4-(methylthio)butyl)dithio)methyl)-1-oxo-3-phenylpropyl)-, phenylmethyl ester, RB-101, RB101 
National Institutes of Health

Related topics

Related topics

5 relations

Broader (4)

AnalgesicsDisulfidesEnzyme InhibitorsPhenylalanine
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Oxytocin as a Potential Therapeutic Target for Schizophrenia and Other Neuropsychiatric Conditions
Oxytocin as a Potential Therapeutic Target for Schizophrenia and Other Neuropsychiatric Conditions 
Review
2007
Review
2007
RB101-mediated protection of endogenous opioids: potential therapeutic utility?
The endogenous opioids met- and leu-enkephalin are inactivated by peptidases preventing the activation of opioid receptors… 
2007
2007
Blockade of morphine‐induced behavioral sensitization by a combination of amisulpride and RB101, comparison with classical opioid maintenance treatments
Maintenance treatments with methadone or buprenorphine are more or less efficient procedures for helping heroin addicts to stop… 
2003
2003
Further evidence for the interaction of μ- and δ-opioid receptors in the antinociceptive effects of the dual inhibitor of enkephalin catabolism, RB101(S) A spinal c-Fos protein study in the rat under…
2002
2002
RB101(S), a dual inhibitor of enkephalinases does not induce antinociceptive tolerance, or cross-tolerance with morphine: a c-Fos study at the spinal level.
2001
2001
Effects of the potent analgesic enkephalin-catabolizing enzyme inhibitors RB101 and kelatorphan on respiration
2001
2001
Facilitation of enkephalins catabolism inhibitor-induced antinociception by drugs classically used in pain management
1999
1999
The effects of RB101, a mixed inhibitor of enkephalin-catabolizing enzymes, on carrageenin-induced spinal c-Fos expression are completely blocked by β-funaltrexamine, a selective μ-opioid receptor…
Highly Cited
1992
Highly Cited
1992
Repeated systemic administration of the mixed inhibitor of enkephalin-degrading enzymes, RB101, does not induce either antinociceptive tolerance or cross-tolerance with morphine.
1992
1992
Lack of physical dependence in mice after repeated systemic administration of the mixed inhibitor prodrug of enkephalin-degrading enzymes, RB101.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)